Within-subjects, double-blind, placebo-controlled study (n=65) testing MDMA (0, 0.75, 1.5 mg/kg, to 125 mg) with oxytocin (20 IU) as an active control in healthy volunteers to assess social and emotional processing.
Randomised allocation was not used; this is a within-subjects, double-blind, double-dummy experiment in healthy volunteers (n=65) comparing two active MDMA doses, oxytocin 20 IU, and placebo to characterise empathogenic effects.
Primary measures assess emotion recognition, emotional responsiveness and sociability; safety monitoring included ECG and medical screening. MDMA dosing used 0.75 and 1.5 mg/kg (capped at 125 mg).
Within-subjects, double-blind, double-dummy crossover: each participant received MDMA (0, 0.75, 1.5 mg/kg; cap 125 mg), oxytocin (20 IU), and placebo across sessions.
Also includes 0.75 mg/kg MDMA sessions and placebo; dose capped at 125 mg.
Oxytocin 20 IU (intranasal) used as active control (encoded as placebo reference with note).
Placebo sessions (matched double-dummy).